Amsterdam’s specialist cancer hospital, the Antoni van Leeuwenhoek, has received millions of euros in damages in a secret settlement with a Japanese pharmaceuticals firm, the Telegraaf said on Wednesday.

The payment was made in connection with fraud relating to royalty payments on a breast cancer test developed in the Netherlands that had lasted for 25 years, the paper said. The test allows doctors to monitor how a patient is responding to treatment.

The hospital has confirmed the settlement to the Telegraaf but will not comment on the size of the payment. However, sources told the paper that the deal is for more than €10m. Last year, judges in Amsterdam ruled in favour of the hospital and told Fujirebio to reach a deal.

Fujirebio, which is listed on the Tokyio stock exchange, has been selling the testing kits based on AvL research since 1984. According to the Financieele Dagblad last year, the AVL royalty should have amounted to 4% of the income from the test.